focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEGI.L Regulatory News (EGI)

  • There is currently no data for EGI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

$2.5 million order from ElMindA Ltd

15 Oct 2015 07:20

RNS Number : 3438C
Electrical Geodesics, Inc
15 October 2015
 



Electrical Geodesics, Inc.

 

 

$2.5 million order from ElMindA Ltd for GES 400 systems

 

Single largest order in EGI's history

 

Market demand grows for ElMindA's Brain Network Activation (BNA™) Analysis System -

a new tool for tracking brain function over time

 

EUGENE, OREGON, US, 15 October 2015 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading developer and supplier of neuro-diagnostic and neuro-modulation technologies, today announced that it has received a $2.5 million order to supply GES-400 systems under a new supply agreement, which extends the scope of the umbrella agreement with ElMindA Ltd. announced in January 2015.

 

ElMindA is a US and Israel-based company which introduced the Brain Network Activation (BNA™) analysis system, that received FDA clearance in 2014 for the assessment of brain function in 14- to 24-year-olds. BNA is currently available in nine US markets including Chicago, Los Angeles, Philadelphia, Connecticut, Michigan, Minneapolis, Palm Beach FL, and Phoenix. The system is also being implemented in leading research labs in the US and globally.

EGI has supplied a number of dense-array systems under the initial, two-year contract with ElMindA. The early success of the BNA, which incorporated EGI's non-invasive, multi-channel EEG technology, has led ElMindA to increase its orders by a minimum of $2.5 million of the GES- 400 systems from EGI over the next 12 months with the first half of the order anticipated to be fulfilled in 2015.

EGI's non-invasive, multi-channel EEG technology coupled with ElMindA's advanced signal processing, machine-learning and analysis algorithms, measures patterns of neuronal networks activated during specific brain processes. Using its' proprietary database of over 11,000 data sets, the BNA analysis system delivers both quantitative and qualitative insights into brain function. This breakthrough technology provides new information on brain functionality to potentially aid physicians to identify and manage a range of neurological disorders.

Don Tucker, CEO of EGI, commented: "We have worked closely with ElMindA during 2015 to align our technologies and are delighted to see the initial commercial success that has given them the confidence to make this minimum $2.5 million purchase commitment which is the largest individual order in EGI's history. ElMindA and its' customers recognize the significant value that the precision dense array EEG brings to the objective assessment of brain disorders and injuries. We believe that by working together we can bring both our technologies into wider use and drive further revenues for both companies as the practical value of precise EEG analysis becomes further adopted by clinical practitioners."

 

"We are encouraged with both the clinical and commercial interest we are seeing for the BNA system, and this has given us the confidence to expand our relationship with EGI," said Ronen Gadot, CEO of ElMindA. "The BNA™ test enables physicians to view changes in brain functionality. Along with routine testing, it offers another layer of objective insight to help physicians make better-informed decisions. We are pleased to collaborate with a partner that provides such cost effective, reliable technology and look forward to many years of continued growth."

 

For more information contact:

 

EGI

US: Ann Bunnenberg, COO and President

+1 (0) 541 687 7962

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

James Steel, Tom Burt

FTI Consulting (PR Advisors)

+44 (0) 20 3727 1000

Simon Conway, Mo Noonan

 

 

Notes to Editors

 

Electrical Geodesics, Inc. in Summary

 

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic and neuromodulation products used to monitor, interpret and modulate brain activity, based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

 

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalise on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

 

See our website www.egi.com

 

 

ElMindA Ltd.

 

ElMindA was founded in 2006 to address an unmet need for objectively assessing brain health and brain-related disorders over the course of an individual's lifetime. ElMindA translates state-of-the-art neuroscience via advanced algorithmic science into clinically meaningful Brain Network Activation (BNA™) maps. The BNA Analysis System is to be used by qualified medical professionals for the post-hoc analysis of the human Electroencephalogram (EEG), utilizing evoked response potentials (ERP). The device is indicated in the US for use in individuals 14 to 24 years of age with the Auditory Oddball task only. ElMindA is a preferred partner of industry-leading organizations based on the rigor of its science and technology development

 

 

Glossary

 

EEG

Electroencephalography

dEEG

Dense-array EEG

MRI

Magnetic resonance imaging

fMRI

Functional MRI

PET

Positron emission tomography

MEG

Magneto encephalography

NIRS

Near-infra-red spectroscopy

TES

Trans-cranial electrical stimulation

TMS

Trans-cranial magnetic stimulation

 

.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQELBFEBFFFBQ
12
Date   Source Headline
21st Jul 201711:00 amRNSRe Cancellation Date
20th Jul 20177:30 amRNSSuspension - Electrical Geodesics Inc
18th Jul 20177:00 amRNSResult of Special Meeting
13th Jul 20176:21 pmRNSExtension of Time to Return Form of Declarations
26th Jun 20171:40 pmRNSPosting of Proxy Statement
22nd Jun 20177:00 amRNSRecommended Offer for Electrical Geodesics, Inc
24th Apr 20177:00 amRNSAnnual Financial Report
20th Apr 20177:00 amRNSFinal Results
5th Apr 20176:15 pmRNSNotice of Results
28th Mar 20177:00 amRNSPreliminary Results of the Epilepsy Trial
6th Mar 20177:00 amRNSBusiness Update
13th Jan 20177:00 amRNSTrading Update
26th Aug 20167:00 amRNSHalf-year Report
28th Jul 20167:00 amRNSTrading Update
21st Jun 20167:39 amRNSResult of AGM
10th May 20167:59 amRNSNotice of AGM
29th Apr 20167:30 amRNSAnnual Financial Report
30th Mar 201612:09 pmRNSAnnual Financial Report
29th Mar 201612:30 pmRNSNotice of Results
9th Feb 20167:00 amRNSTrading Update
30th Nov 20158:50 amRNSHolding(s) in Company
15th Oct 20157:20 amRNS$2.5 million order from ElMindA Ltd
5th Oct 20158:00 amRNSNotification of change of TIDM
15th Sep 20157:00 amRNSInterim Results
7th Sep 20153:00 pmRNSRe Trading Share Lines
3rd Jul 20159:24 amRNSAGM Results
2nd Jul 201512:35 pmRNSAGM Statement
17th Jun 20155:56 pmRNSNotice of AGM
24th Apr 20152:57 pmRNSTransfer of shares between lines of stock
22nd Apr 20157:00 amRNSDistribution Agreement with EB Neuro
24th Mar 20157:00 amRNSFinal Results
16th Mar 20154:37 pmRNSResult of Special Meeting
6th Mar 201510:52 amRNSIssue of Equity
2nd Mar 20157:00 amRNSIDE Clearance from FDA to Commence Trials on GTEN
22nd Jan 20157:00 amRNSGES400 platform to support ElMindA's BNAT platform
19th Jan 20152:39 pmRNSTransfer of shares between lines of stock
15th Jan 20157:00 amRNSTrading Update
14th Jan 20154:38 pmRNSTransfer of shares between lines of stock
22nd Dec 20147:00 amRNSTrading Update
2nd Dec 20143:50 pmRNSTransfer of shares between lines of stock
2nd Oct 20147:00 amRNSFeasibility Study of GTEN 100 Neuromodulation
25th Sep 20147:00 amRNS$1.7m Extension of SBIR grant from NIMH
22nd Sep 20147:00 amRNSIntroduction of Unrestricted Share Trading Line
10th Sep 20147:00 amRNSHalf Yearly Report
16th Jul 20147:00 amRNSTrading Statement
15th Jul 20147:00 amRNS$1.75m Phase II SBIR grant from NINDS/NIH
17th Jun 20148:00 amRNSAGM Results
12th Jun 20147:00 amRNSDistribution Agreement with Soterix Medical
6th Jun 20147:00 amRNSShowcasing of GTEN Neuromodulation Technology
16th May 20142:56 pmRNSNotice of AGM
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.